{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T02:22:01Z","timestamp":1772245321910,"version":"3.50.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1007\/s10557-017-6727-0","type":"journal-article","created":{"date-parts":[[2017,5,2]],"date-time":"2017-05-02T21:13:22Z","timestamp":1493759602000},"page":"187-195","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Identification and Management of Statin-Associated Symptoms in Clinical Practice: Extension of a Clinician Survey to 12 Further Countries"],"prefix":"10.1007","volume":"31","author":[{"given":"Robert S.","family":"Rosenson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shravanthi R.","family":"Gandra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"McKendrick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo","family":"Dent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather","family":"Wieffer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lung-I","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberico L.","family":"Catapano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Oh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Kees Hovingh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik S.","family":"Stroes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,5,3]]},"reference":[{"key":"6727_CR1","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.atherosclerosis.2016.05.037","volume":"252","author":"MF Piepoli","year":"2016","unstructured":"Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. European guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Atherosclerosis. 2016;252:207\u201374.","journal-title":"Atherosclerosis"},{"key":"6727_CR2","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.atherosclerosis.2016.08.018","volume":"253","author":"AL Catapano","year":"2016","unstructured":"Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, et al. ESC\/EAS guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Atherosclerosis. 2016;253:281\u2013344.","journal-title":"Atherosclerosis"},{"issue":"9493","key":"6727_CR3","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","volume":"366","author":"C Baigent","year":"2005","unstructured":"Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267\u201378.","journal-title":"Lancet"},{"issue":"10059","key":"6727_CR4","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","volume":"388","author":"R Collins","year":"2016","unstructured":"Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388(10059):2532\u201361.","journal-title":"Lancet"},{"issue":"7","key":"6727_CR5","doi-asserted-by":"crossref","first-page":"526","DOI":"10.7326\/0003-4819-158-7-201304020-00004","volume":"158","author":"H Zhang","year":"2013","unstructured":"Zhang H, Plutzky J, Skentzos S, Morrison F, Mar P, Shubina M, et al. Discontinuation of statins in routine care settings: a cohort study. Ann Intern Med. 2013;158(7):526\u201334.","journal-title":"Ann Intern Med"},{"issue":"9","key":"6727_CR6","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.numecd.2012.04.012","volume":"23","author":"D Rosenbaum","year":"2013","unstructured":"Rosenbaum D, Dallongeville J, Sabouret P, Bruckert E. Discontinuation of statin therapy due to muscular side effects: a survey in real life. Nutr Metab Cardiovasc Dis. 2013;23(9):871\u20135.","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"8","key":"6727_CR7","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/j.clinthera.2007.08.022","volume":"29","author":"GA Nichols","year":"2007","unstructured":"Nichols GA, Koro CE. Does statin therapy initiation increase the risk for myopathy? An observational study of 32,225 diabetic and nondiabetic patients. Clin Ther. 2007;29(8):1761\u201370.","journal-title":"Clin Ther"},{"issue":"6","key":"6727_CR8","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10557-005-5686-z","volume":"19","author":"E Bruckert","year":"2005","unstructured":"Bruckert E, Hayem G, Dejager S, Yau C, Begaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients\u2014the PRIMO study. Cardiovasc Drugs Ther. 2005;19(6):403\u201314.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"7 Suppl","key":"6727_CR9","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1016\/j.cjca.2016.01.003","volume":"32","author":"GB Mancini","year":"2016","unstructured":"Mancini GB, Baker S, Bergeron J, Fitchett D, Frohlich J, Genest J, et al. Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Consensus Working Group Update (2016). Can J Cardiol. 2016;32(7 Suppl):S35\u201365.","journal-title":"Can J Cardiol"},{"issue":"17","key":"6727_CR10","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","volume":"36","author":"ES Stroes","year":"2015","unstructured":"Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK, et al. Statin-associated muscle symptoms: impact on statin therapy\u2014European Atherosclerosis Society Consensus Panel statement on assessment. Aetiology and Management Eur Heart J. 2015;36(17):1012\u201322.","journal-title":"Aetiology and Management Eur Heart J"},{"issue":"3 Suppl","key":"6727_CR11","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.jacl.2014.03.004","volume":"8","author":"RS Rosenson","year":"2014","unstructured":"Rosenson RS, Baker SK, Jacobson TA, Kopecky SL, Parker BA, The National Lipid Association\u2019s Muscle Safety Expert Panel. An assessment by the Statin Muscle Safety Task Force: 2014 update. J Clin Lipidol. 2014;8(3 Suppl):S58\u201371.","journal-title":"J Clin Lipidol."},{"issue":"1","key":"6727_CR12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5114\/aoms.2015.49807","volume":"11","author":"M Banach","year":"2015","unstructured":"Banach M, Rizzo M, Toth PP, Farnier M, Davidson MH, Al-Rasadi K, et al. Statin intolerance\u2014an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Arch Med Sci. 2015;11(1):1\u201323.","journal-title":"Arch Med Sci"},{"issue":"4","key":"6727_CR13","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/bcp.12339","volume":"78","author":"MA De Vera","year":"2014","unstructured":"De Vera MA, Bhole V, Burns LC, Lacaille D. Impact of statin adherence on cardiovascular disease and mortality outcomes: a systematic review. Br J Clin Pharmacol. 2014;78(4):684\u201398.","journal-title":"Br J Clin Pharmacol"},{"issue":"11","key":"6727_CR14","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.jacc.2016.12.036","volume":"69","author":"M-C Serban","year":"2017","unstructured":"Serban M-C, Colantonio LD, Manthripragada AD, Monda KL, Bittner VA, Banach M, et al. Statin intolerance and risk of coronary heart events and all-cause mortality following myocardial infarction. J Am Coll Cardiol. 2017;69(11):1386\u201395.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"6727_CR15","first-page":"447","volume":"17","author":"MM Gulizia","year":"2016","unstructured":"Gulizia MM, Colivicchi F, Arca M, Abrignani MG, Perna GP, Mureddu GF, et al. ANMCO position paper: diagnostic and therapeutic pathways in patients with hypercholesterolemia and statin intolerance. G Ital Cardiol (Rome). 2016;17(6):447\u201355.","journal-title":"G Ital Cardiol (Rome)"},{"issue":"3 Suppl","key":"6727_CR16","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1016\/j.jacl.2014.03.002","volume":"8","author":"JR Guyton","year":"2014","unstructured":"Guyton JR, Bays HE, Grundy SM, Jacobson TA, The National Lipid Association Statin Intolerance Panel. An assessment by the Statin Intolerance Panel: 2014 update. J Clin Lipidol. 2014;8(3 Suppl):S72\u201381.","journal-title":"J Clin Lipidol"},{"key":"6727_CR17","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.atherosclerosis.2015.12.015","volume":"245","author":"GK Hovingh","year":"2016","unstructured":"Hovingh GK, Gandra SR, McKendrick J, Dent R, Wieffer H, Catapano AL, et al. Identification and management of patients with statin-associated symptoms in clinical practice: a clinician survey. Atherosclerosis. 2016;245:111\u20137.","journal-title":"Atherosclerosis"},{"key":"6727_CR18","doi-asserted-by":"crossref","unstructured":"Rosenson RSM K, Bayliss, M., Sanchez, R., Baccara-Dinet, M.T., Chibedi-De-Roche, D, Taylor, B., Khan, I., Manvelian, G., White, M., Jacobson, T.A. The Statin-Associated Muscle Symptom (SAMS) Clinical Index: Revision for clinical use, content validation, and inter-rate reliability. Cardiovasc Drugs Ther. 2017;31.","DOI":"10.1007\/s10557-017-6723-4"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-017-6727-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10557-017-6727-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-017-6727-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,5,11]],"date-time":"2017-05-11T13:06:58Z","timestamp":1494508018000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10557-017-6727-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["6727"],"URL":"https:\/\/doi.org\/10.1007\/s10557-017-6727-0","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4]]}}}